12:00 AM
Jun 25, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Horizon Pharma, Covidien sales and marketing update

Horizon granted Covidien's Mallinckrodt LLC pharmaceutical business non-exclusive rights to co-promote Duexis ibuprofen/famotidine in the U.S. through Dec. 31, 2014, for the relief of signs and symptoms...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >